Products
Pipeline
Our pipeline prioritizes BIOX-101, which has completed Phase 2a testing for patients with intracerebral hemorrhage (ICH) and has been granted Orphan Drug Designation (ODD) for ICH in the U.S. and in Europe. Bioxodes is planning to start a Phase 2b trial with BIOX-101 in ICH early in 2027.
Based on the unique mechanism of action of BIOX-101, and particularly its effect on neutrophils, we aim to build an innovative pipeline with drug candidates for the prevention of thrombo-inflammatory and inflammatory diseases.